Objective. We sought to identify the microRNA (miRNA) profile and potential biomarkers in FMF and to clarify their gene targets to elucidate the pathogenesis of FMF.
Introduction
FMF is an inherited autoinflammatory disorder characterized by recurrent attacks of fever with arthritis, abdominal pain, skin rash and/or serositis [1, 2] . FMF is caused by a number of mutations of the Mediterranean Fever (MEFV) gene, coding a protein named pyrin that acts as a major regulatory component of the inflammasome [3] . Accordingly, the pathological condition of FMF is thought to be mainly an abnormal activation of the inflammasome caused by mutations of pyrin, but refractory cases occur despite the absence of genetic mutations in the MEFV gene.
FMF patients have been reported to show an increased serum level of inflammatory cytokines such as IL-1b, IL-6, IL-17 and IL-18 [46] . With the use of a multisuspension cytokine array, we recently revealed the specific cytokine network among patients with FMF [7] , but a specific biomarker for evaluating the disease activity of FMF is not yet available. In addition, the precise molecular mechanisms that underlie the aberrant levels of inflammatory cytokines during FMF attacks have not been established.
MicroRNAs (miRNAs) are endogenous small RNAs that post-transcriptionally regulate gene expression by pairing with a target [8] . Importantly, miRNAs are present not only in cells but also in various biofluids, including blood serum, as extracellular miRNAs [9] . Although the precise mechanisms of the release of cellular miRNAs to the extracellular environment remain largely unknown, emerging evidence has suggested an association of aberrantly expressed circulating miRNAs in the serum with the pathogenesis or progression of diseases including cancer [10] and autoimmune diseases [11, 12] . Although a number of circulating miRNAs associated with inflammation have been identified [13, 14] , their roles in individuals with FMF and the underlying mechanism remain to be elucidated.
In the present study, to identify the utility of circulating miRNAs for clinical application and to clarify the function and regulation of these miRNAs, we performed an miRNA microarray in the serum of both FMF patients in attack and those in remission. Our results revealed that miR-204-3p was the most important miRNA during attack, and we subsequently clarified the roles of miR-204-3p by performing in vitro experiments, including a complementary DNA (cDNA) microarray and bioinformatic analysis. Our findings demonstrated that miR-204-3p is one of the most downregulated miRNAs in the attacks of FMF patients and that miR-204-3p regulates the production of toll-like receptor (TLR) 4-related inflammatory cytokines by targeting 3 0 -UTR regions of PIK3CG. These data thus suggest that miR-204-3p serves as a suppressor of inflammatory cytokine production in FMF by targeting the PI3Kg pathway.
Methods

Patients and controls
We obtained serum samples from 9 FMF patients, 12 gender-and age-matched RA patients as a disease control and 19 gender-and age-matched healthy donors between May 2014 and October 2016 at Nagasaki University, Nagasaki Medical Center, Sasebo Chuo Hospital, Sasebo City General Hospital, Shinshu University and Kanazawa University. FMF was diagnosed according to the Tel Hashomer criteria [15, 16] , and clinically active RA patients who met the ACR 1987 criteria [17] or the 2010 ACR/EULAR RA classification criteria [18] were recruited from Nagasaki University. Patients with RA were treated at the discretion of their doctor and specific medications included one or more of the following: SSZ, MTX, systemic corticosteroids and NSAIDs. There was no RA patient treated with biologic agents. Serum samples were centrifuged at 3000 g for 10 min and the supernatants were collected and stored at À80 C before the assay was performed.
This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (http://www.umin.ac.jp/ctr/) as UMIN000015881. All patients gave their signed informed consent to be subjected to the protocol, which was approved by the Institutional Review Board of Nagasaki University (approval no. 14092956-3) and the related centres. 
RNA extraction
Total RNA from the cell lines was extracted using a mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) and from 200 ml of serum using a MicroRNA Extractor SP Kit (Wako, Osaka, Japan) according to the manufacturer's protocol. RNA concentrations and quality were determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The RNA samples were stored at À80 C until the reverse transcription reaction.
miRNA microarray analysis and quantitative real-time PCR
The miRNA expression profiles in the serum from FMF patients in attack and in remission were examined with the use of a commercially available miRNA microarray analysis system (3D-Gene miRNA labelling kit, human_miRNA_V20, Toray, Tokyo, Japan). We analysed the data produced by the microarray analysis and then selected candidate miRNAs whose levels in the serum were markedly upregulated (>5-fold) or downregulated (<1/5-fold) in attack compared with those in remission for further analysis.
cDNA was synthetized from total RNA using a TaqMan Advanced miRNA cDNA Synthesis Kit (Applied Biosystems, Foster City, CA, USA). We assayed the expression of mature miRNAs by performing TaqMan Advanced MicroRNA Assays (Applied Biosystems) with specific primers and probes. All primers and probes were from Applied Biosystems: has-miR-204-3p, hasmiR-155, RNU6B and has-miR-191-5p. The RNU6B expression of the cell lines and the has-miR-191-5p expression of the serum were used as endogenous controls. Gene expressions were assessed by the comparative CT method.
Gene microarray analysis
The RNA was obtained from THP-1 cells after LPS stimulation. Total cellular RNA was extracted using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). We performed the cDNA microarray using the SurePrint G3 Human GE 8x60K Microarray (Agilent Technologies, Santa Clara, CA, USA). The in vitro transcription, oligonucleotide array hybridization and scanning were conducted with Takara Bio protocols (TaKaRa Bio, Shiga, Japan). The data have been deposited in the Gene Expression Omnibus repository (GSE98940).
Multiplex cytokine assay
We measured inflammatory cytokines in the supernatant from LPS-stimulated THP-1 cells and monocytes from FMF patients by performing a multiplex cytokine bead assay. We used blindly and in parallel the Bio-plex Pro Human Cytokine assay (Bio-Rad, Hercules, CA, USA) and Milliplex MAP Human Cytokine/Chemokine panel 1 (Millipore, Billerica, MA, USA) according to the manufacturers' instructions.
Luciferase activity assay
For the generation of pMIR-PIK3CG-3 0 -UTR vector, a 483 base pair of the dsDNA fragment encoding the 3 0 -UTR of PIK3CG containing the miR-204-3p target site was synthesized (GenScript, Piscataway, NJ, USA) and was subcloned into the pMirTarget vector (OriGene Technology, Rockville, MD, USA) between the SgfI and MluI sites. For the generation of pMIR-PIK3CG-3 0 -UTR mutant vectors, the sequence including the miR-204-3p target site of the 3 0 -UTR of PIK3CG used was changed from 5 0 -TTCCCAGA-3 0 to 5 0 -TTAGGCGA-3 0 . In total, 50 000 HEK-293F cells were seeded into 24-well plates 24 h prior to transfection. Cells were co-transfected with 100 ng of pMIR-PIK3CG-3 0 -UTR or pMIR-PIK3CG-3 0 -UTR mutant vectors, 50 ng of pRL-TK vector (Promega, Madison, WI, USA) containing Renilla luciferase and 40 nM of miR-204-3p precursor molecule or 40 nM of negative control using Lipofectamine RNAiMAX (Life Technologies). After a 24 h transfection, luciferase activity was detected using the Dual-Glo Luciferase Reporter Assay system (Promega) according to the manufacturer's protocol. Firefly luciferase activity was normalized to Renilla luciferase activity.
Western blotting
CD14
+ monocytes from FMF patients isolated by magnetic cell sorting (CD14 MicroBeads kit; Miltenyi Biotec, BergischGladbach, Germany) were stimulated with LPS in the presence or absence of PI3Kg inhibitor (AS-605240, SigmaAldrich, Bornem, Belgium) or a specific inhibitor of caspase-1, acetyl-tyrosyl-valyl-alanyl-aspartyl-chloromethylketone (ac-YVAD-cmk) (Sigma-Aldrich). These cells were lysed in radioimmunoprecipitation assay buffer at 4 C for 30 min. After centrifugation (16 400 g, 30 min, 4 C), supernatants were collected and an identical amount of protein from each lysate (5 mg/well) was separated on NuPAGE 412% Bis-Tris Gel (Life Technologies).
Proteins were transferred to a nitrocellulose membrane using an iBlot 2 dry transfer system (ThermoFisher Scientific, Waltham, MA, USA). Membranes were probed with primary antibodies: rabbit anti-PIK3CG (Cell Signaling Technology, Beverly, MA, USA), rabbit antiphospho(Ser473)-PIK3CG (Cell Signaling Technology) and rabbit anti-actin (Sigma-Aldrich) and with the secondary antibody goat-anti-rabbit IgG horseradish peroxidaseconjugated antibody (Jackson Immunoresearch, West Grove, PA, USA). Blocking, staining and washing were done overnight using an iBind Flex Western device and reagents following the manufacturer's protocol (ThermoFisher Scientific). ECL Select Western Blotting Detection Reagent (Amersham, Arlington Heights, IL, USA) was used for detection.
Flow cytometric detection of apoptosis
Using an Annexin V/7-AAD Apoptosis Detection Kit (BioLegend, San Diego, CA, USA), the apoptotic cells were evaluated by flow cytometry analysis. The data were analysed using FlowJo software (Tree Star Software, San Carlos, CA, USA).
Statistical analysis
The clinical characteristics of the FMF patients and the RA patients were compared with Fisher's exact test for discrete variables and with Wilcoxon's test for continuous variables. The non-parametric Spearman's rank correlation analysis was performed in the analysis of correlations. We used the two-tailed Student's t test and MannWhitney U test to analyse the differences between two groups. Differences among three datasets were analysed by oneway analysis of variance. All statistical analyses were performed using JMP Pro 11.2 (SAS Institute, Cary, NC, USA) and GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) software. P-values <0.05 were considered significant.
Results
Serum from FMF patients showed a decreased level of miR-204-3p during attack
To explore the miRNA profile in the serum during attacks of FMF, we performed a microarray analysis of miRNA expression. As shown in Fig. 1A , we found that miR-204-3p (attack, 389.1; remission, 5095.3; ratio, 15.7), miR-1260b (attack, 29.5; remission, 171.2; ratio, 7.0) and miR-4476 (attack, 13.7; remission, 72.8; ratio, 6.36) were greatly decreased in the serum from FMF patients in attack. We selected these miRNAs for the validation study among patients with FMF by quantitative PCR (qPCR) and found that neither miR-1260b nor miR-4476 was detectable both in attack and in remission, whereas the expression of miR-204-3p was decreased during attack (data not shown).
To further validate these findings, we compared the levels of miR-204-3p in the serum among the healthy controls, RA patients and FMF patients. Table 1 shows the characteristics of the FMF and RA patients. Of the nine FMF patients, six (67%) were female. The FMF patients' median age at onset was 22 years and their median age at diagnosis was 34 years. Their median serum CRP level during attack was 6.6 mg/dl. The serum levels of miR-204-3p were found to be significantly higher in the FMF patients compared with the healthy controls and RA patients (Fig. 1B) . In addition, we evaluated the relationship between the international severity score for FMF [19] and the serum levels of miR-204-3p and found that there was a significant negative correlation between these two variables (Fig. 1C) . Taken together, these data indicate that miR-204-3p is an important miRNA in FMF during attack and has potential as a diagnostic biomarker of FMF.
The effect of miR-204-3p in macrophages derived from THP-1 cells on cytokine profiles
The decreased expression of circulating miR-204-3p in FMF attacks indicated that this miRNA has some roles in mitigating inflammation. To test this hypothesis we examined the level of miR-204-3p after stimulation related to inflammasome formation by performing an in vitro experiment. We stimulated macrophages derived from THP-1 cells with LPS, ATP and LPS + ATP and found that the expression of miR-204-3p was significantly suppressed by LPS stimulation and not by ATP stimulation (Fig. 2A) . The expression of miR-155, which is known as an LPSinduced miRNA in THP-1 cells [20] , was induced by LPS but not by ATP stimulation (Fig. 2B) . We then investigated whether miR-204-3p can be induced with physiologically low concentrations of LPS and found that even at low concentrations of LPS, it significantly inhibited the induction of miR-204-3p 18 h after stimulation (Fig. 2C) .
We also measured the cytokine profiles after the induction of miR-204-3p. THP-1 cells transfected with miR-204-3p precursor or the negative control were stimulated with LPS for 24 h. The results demonstrated no significant differences in the expression of TNF-a, G-CSF and IL-18 (Fig. 2EH, J and K) . In contrast, the induction of miR-204-3p significantly inhibited the production of IL-6 ( Fig. 2D ) and IL-12p40 (Fig. 2I) .
Identification of target genes of miR-204-3p by cDNA microarray analysis
To clarify the cause of the inflammatory cytokine reduction with pre-miR-204-3p treatment, we attempted to determine the target genes of miR-204-3p. We used a cDNA microarray analysis to search for target mRNAs, the levels of which might decrease according to exogenous miRNA expression. We transfected THP-1 cells with pre-miR-204-3p and carried out a cDNA microarray analysis (Gene Expression Omnibus accession no. GSE). Fifty-three genes were upregulated (>1.5-fold) and 77 genes were downregulated ( < À1.5-fold) by ectopic miR-204-3p expression. The pathway analysis indicated that some inflammasome-related pathways, including the TLR signalling pathway (P = 0.0023), IL-1 signalling pathway (P = 0.020) and IL-6 signalling pathway (P = 0.047) were downregulated by miR-204-3p. Fig. 3A shows the heat map of the expression of TLR-related genes in macrophages derived from THP-1 cells. We validated the microarray results by performing a qPCR analysis with pre-miR-204-3p transfection into macrophages derived from THP-1 cells (Fig. 3B) . Collectively, our data indicate that miR-204-3p may target genes implicated in the TLR pathway.
PIK3CG is a target of miR-204-3p in THP-1 cells
To alternatively predict the target genes of miR-204-3p, we performed computational searches of miRNA target databases (miRBase and TargetScan), and the results identified PIK3CG as a putative target of miR-204-3p (Fig. 4A) . To determine whether the predicted target sites for miR-204-3p in the 3 0 -UTRs of PIK3CG mRNAs were responsible for the translational repression, we performed dual luciferase reporter assays with vectors containing the 3 0 -UTR target sites downstream of the luciferase reporter gene. We found that the luciferase activity was significantly decreased in THP-1 cells co-transfected with pre-miR-204-3p and a reporter vector containing the PIK3CG 3 0 -UTR target site (Fig. 4B ). In contrast, the introduction of a mutation that disrupted the miR-204-3p seed sequence completely abrogated its ability to inhibit luciferase activity (Fig. 4B) . Together, these results suggest that miR-204-3p suppresses the expression of PIK3CG by directly binding to its 3 0 -UTR.
Inhibition of PI3Kg mitigates the production of IL-6 and IL-12p40 in CD14 + monocytes from FMF patients
To determine whether PI3Kg is involved in the pathogenesis of FMF, we examined whether PI3Kg was phosphorylated by LPS stimulation in CD14 + monocytes from FMF patients. As shown in Fig. 5A , the phosphorylation of PI3Kg was induced 30 min after LPS stimulation and this phosphorylation was inhibited by the PI3Kg inhibitor AS605240.
We next examined the effect of PI3Kg inhibition as well as that of a specific inhibitor of caspase-1, YVAD, on the production of inflammatory cytokines by CD14 + monocytes from FMF patients. We found that the production of IL-6 and IL-12p40 after LPS stimulation were significantly decreased in the cells treated with AS605240 ( Fig. 5B and C) , whereas the levels of IL-1b and TNF-a after LPS stimulation were not changed in the presence of AS-605240 ( Fig. 5D and E). Collectively these findings indicate that PI3Kg signalling is involved in the production of TLR4-related cytokines in CD14 monocytes from FMF patients.
Effect Fig. S1 , available at Rheumatology online). These findings indicate that miR-204-3p inhibit inflammatory cytokines by a mechanism independent of apoptosis.
Discussion
There is accumulating evidence about the function and biology of circulating miRNAs in the serum as a potential 9 (100) MEFV mutation in exon 10, n (%) regulator of developmental processes and as a promising biomarker for several diseases [22, 23] . Our present findings demonstrated that miR-204-3p was greatly decreased in the serum from FMF patients in attack and that the expression of miR-204-3p was suppressed by LPS stimulation. Importantly, this is the first study to identify the regulation of PI3Kg by miR-204-3p and to validate the role of PI3Kg in TLR4-related cytokine production by monocytes from FMF patients. The function of miR-204-3p has not been fully elucidated. Although previous reports showed that miR-204-3p targets the IGFBP2/AKT/Bcl2 pathway [24] and miR-204-3p inhibits the growth of hepatocellular carcinoma tumour endothelial cells [25] , the significance of miR-204-3p in the pathology of autoinflammatory diseases is not clear. In the present study, we observed that the expression of circulating miR-204-3p was significantly decreased in FMF patients in attack compared with the RA patients and healthy individuals. This observation indicates that miR-204-3p has some role in the suppression of inflammation, but it remains unknown whether miR-204-3p directly mitigates inflammation and whether the inflammation results in a decreased expression of miR-204-3p in the serum.
In addition to the recognition of cytoplasmic danger signals by nucleotide-binding oligomerization domainlike receptors, the recognition of pathogen-associated molecular patterns such as LPS, peptidoglycan and polyI:C by TLRs is necessary for the upregulation of inflammasome components. In our in vitro experiments, miR-204-3p was induced by LPS and we observed a reduction of inflammatory cytokines by the induction of miR-204-3p. In line with our observations, a recent report showed that miR-204-3p was induced by stimulation via the STAT3 pathway, which is involved in TLR4 signalling [26] . Our present analysis of inflammatory cytokines in THP-1 cells revealed that the induction of miR-204-3p significantly decreased the expressions of IL-6 and IL-12p40 induced by LPS stimulation, indicating that miR-204-3p affects the first priming signals induced by TLRs.
PI3Kg has important roles in inflammatory responses, including the activation, proliferation and migration of inflammatory cells. In line with these observations, it has been demonstrated that the inhibition of PI3Kg resulted in the mitigation of several autoimmune and inflammatory diseases in murine models including RA [27] , SLE [28, 29] , multiple sclerosis [30] , type 1 diabetes [31] , cardiovascular disease [32] and experimental colitis [33, 34] . The results of the present study demonstrated that PI3Kg is a target molecule of miR-204-3p, which decreases during FMF attacks, and that its inhibition leads to inflammatory cytokine reduction after LPS stimulation in monocytes from FMF patients. The TLR4/PI3Kg/Akt/mTOR pathway activated by LPS is thought to negatively control inflammation in murine macrophages [3537] , but the activity of this pathway was not significantly promoted by miR-204-3p in our present microarray analysis. In addition, the blockage of PI3Kg resulted in decreased production of IL-6 and IL12p40 by macrophages from FMF patients. Further studies are needed to clarify the mechanism by which PI3Kg induces an inflammatory response in human autoinflammatory diseases.
The MEFV gene mutations in FMF patients alter the function of pyrin, which is involved in inflammasomes, leading to induction of IL-1b and IL-18 [38] . A recent clinical trial showed the efficacy of canakinumab, a fully human mAb targeting IL-1b, in patients with colchicineresistant FMF [39] . IL-1b is therefore thought to play a central role in the pathology of FMF with mutation of the MEFV gene, but our present findings indicate that miR-204-3p does not directly influence the activity of the inflammasomes involved in the production of IL-1b and IL-18. Accordingly, although it is difficult to account for the pathology of FMF only by the miR-204-3p-mediated regulation of PI3Kg, recent reports on the efficacy of IL-6 inhibitors in FMF patients [40, 41] support the possibility that inhibiting PI3Kg would affect IL-6 production and may ameliorate some manifestations of FMF.
In conclusion, this study clearly demonstrated that serum miR-204-3p could be a useful biomarker for patients with FMF. This biomarker could have potential for clinical use to predict FMF attacks and to monitor therapeutic responses. Further prospective clinical studies should be conducted to determine whether serum miR-204-3p can distinguish FMF from other inflammatory diseases and to determine the sensitivity and specificity of a measurement of serum miR-204-3p for the evaluation of disease activity. Our study showed that PI3Kg is a target of miR-204-3p and that the inhibition of PI3Kg has potential as a therapeutic target for FMF therapy by regulating TLR4-related inflammatory cytokines including IL-12p40 and IL-6. from FMF patients stimulated with LPS in the presence or absence of AS605240 or YVAD for 18 h. *P < 0.05, **P < 0.01; mean (S.E.M.); n = 4.
